Illinois CancerCare Enrolls First Patients in the World in Clinical Trials for Treatment of Lung Cancer
Peoria, IL July 11, 2016 – Illinois CancerCare today announced enrollment of the first patients in the world in two clinical trials that are studying the efficacy and safety in the treatment of lung cancer. These trials are designed to reflect real-world medical care, embedding the trial into the healthcare setting and utilizing data to produce results that can be used to improve patient care. Others practices participating in these studies are located throughout the United States and in Europe, Asia, Canada and United Kingdom.
“Our team has been and continues to be a leader in cancer research,” states Dr. Madhuri Bajaj. We are excited about exploring these new modalities for lung cancer patients and supporting our goal of delivering innovative treatments that will benefit patients with lung cancer.”
The principle investigators for these clinical trials are Gregory J. Gerstner, MD and Gary R. MacVicar, MD. The specific studies are:
- GO28915 – A Randomized Phase 3 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy.
- GO30081 – A Phase III, Randomized, Double-blind, Placebo-controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Patients with Untreated Extensive Stage Small Cell Lung Cancer.
“Illinois CancerCare has launched these clinical programs to more fully characterize and confirm the benefit-risk profile of this investigational treatment of lung cancer,” stated Gerstner.
“We are excited that we have enrolled the first 2 patients in the world in these two Phase 3 clinical trials and will continue to work with our colleagues around the world to advance the study of the treatment of lung cancer,” stated MacVicar.
